ConductScience.org, home

Paper41598653

Assessing Potential Valve-Preserving Effects of SGLT2 Inhibitors in Degenerative Aortic Stenosis: A Propensity-Matched Study.

Morel O and 8 others. J Clin Med, 2026. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Assessing Potential Valve-Preserving Effects of SGLT2 Inhibitors in Degenerative Aortic Stenosis: A Propensity-Matched Study. Papers, record 41598653. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41598653

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Assessing Potential Valve-Preserving Effects of SGLT2 Inhibitors in Degenerative Aortic Stenosis: A Propensity-Matched Study.
PubMed
Journal
J Clin Med
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
4
iCite
Revised in PubMed
2026-01-31
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Morel OOlivierhttps://orcid.org/0000-0002-7295-3041
2Guglieri MMichael
3Trimaille AAntonin
4Marchandot BBenjaminhttps://orcid.org/0000-0001-7034-1466
5Bisson AArnaud
6Granier AAmandine
7Schini-Kerth VValériehttps://orcid.org/0000-0001-9997-9287
8Bernard AAnne
9Fauchier LLaurenthttps://orcid.org/0000-0002-9267-1658

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References19

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139739876SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO/ROS imbalance.Cardiovasc Res2025https://conductscience.org/library/papers/39739876PubMed
239170957Human Aortic Stenotic Valve-Derived Extracellular Vesicles Induce Endothelial Dysfunction and Thrombogenicity Through AT1R/NADPH Oxidases/SGLT2 Pro-Oxidant Pathway.JACC Basic Transl Sci2024https://conductscience.org/library/papers/39170957PubMed
339565463Could SGLT2 inhibitors improve outcomes in patients with heart failure and significant valvular heart disease? Need for action.Heart Fail Rev2025https://conductscience.org/library/papers/39565463PubMed
439613203Risk of death and thrombosis in patients admitted to the emergency department with supraventricular tachycardias.Heart Rhythm2025https://conductscience.org/library/papers/39613203PubMed
541232829Impact of SGLT2 inhibitors on long-term outcomes in TAVI patients with heart failure: a propensity-matched analysis.Rev Esp Cardiol (Engl Ed)2026https://conductscience.org/library/papers/41232829PubMed
633478648The Pleiotropic Effects of SGLT2 Inhibitors: Remodeling the Treatment of Heart Failure.J Am Coll Cardiol2021https://conductscience.org/library/papers/33478648PubMed
740286382The Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Bioprosthetic Aortic Valve Degeneration.JACC Adv2025https://conductscience.org/library/papers/40286382PubMed
841294140Detrimental Effect of Plasma From Patients With Severe Aortic Stenosis on Valvular Endothelial Cells: Role of Proinflammatory Cytokines and Factor Xa.J Am Heart Assoc2026https://conductscience.org/library/papers/41294140PubMed
941096081Association of SGLT2 Inhibitors with Mortality and Bioprosthesis Valve Failure After TAVR: A Propensity-Matched Cohort Study.J Clin Med2025https://conductscience.org/library/papers/41096081PubMed
1039985508Effect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis.JACC Cardiovasc Interv2025https://conductscience.org/library/papers/39985508PubMed
1139930557GLP-1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity.Diabetes Obes Metab2025https://conductscience.org/library/papers/39930557PubMed
1241392217Dapagliflozin inhibits TGF-β-induced transdifferentiation of valvular interstitial cells and mitral valvular degeneration.J Mol Med (Berl)2025https://conductscience.org/library/papers/41392217PubMed
1338247224Myocardial sodium-glucose cotransporter 2 expression and cardiac remodelling in patients with severe aortic stenosis: The BIO-AS study.Eur J Heart Fail2024https://conductscience.org/library/papers/38247224PubMed
1440908107Vascular effects of SGLT2 inhibitors: evidence and mechanisms.Am J Physiol Cell Physiol2025https://conductscience.org/library/papers/40908107PubMed
1540162639Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation.N Engl J Med2025https://conductscience.org/library/papers/40162639PubMed
1637373620Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes.J Clin Med2023https://conductscience.org/library/papers/37373620PubMed
1735981841Impact of Moderate Aortic Stenosis on Long-Term Clinical Outcomes: A Systematic Review and Meta-Analysis.JACC Cardiovasc Interv2022https://conductscience.org/library/papers/35981841PubMed
1837344038Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.J Am Coll Cardiol2023https://conductscience.org/library/papers/37344038PubMed
1936537038Aortic stenosis and the haemostatic system.Cardiovasc Res2023https://conductscience.org/library/papers/36537038PubMed

Download CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42919410SGLT2 inhibitor therapy following aortic valve intervention for aortic stenosis: a systematic review and meta-analysis of mortality, heart failure, rhythm, renal, and valve-related outcomes.J Cardiothorac Surg2026https://conductscience.org/library/papers/42919410PubMed
42769931Sodium-Glucose Cotransporter-2 Inhibitors in Valvular Heart Disease: From Mechanistic Insights to Clinical Application.J Soc Cardiovasc Angiogr Interv2026https://conductscience.org/library/papers/42769931PubMed
42652758Sodium-Glucose Cotransporter 2 Inhibitors in Valvular Heart Disease: Cardiovascular Benefit, Valve-Specific Effects, and Evidence Gaps-A Structured Narrative Review.J Clin Med2026https://conductscience.org/library/papers/42652758PubMed
42233563SGLT2 Inhibition as a Novel Therapeutic Strategy in Rheumatic Heart Disease.JACC Asia2026https://conductscience.org/library/papers/42233563PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
SLC5A26524PubTator's text mininghttps://conductscience.org/library/genes/6524

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41598653

GET https://conductscience.org/api/papers/v1/41598653/authors